AI models need more data about biology, and OpenAI is paying to create it
OpenAI targets bankrupt biotech data to fuel breakthroughs in predictive biology and medical research.
Last year, the clinical trial policy analyst Ruxandra Teslo posted an idea for super-charging medical AI systems: use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufact...
MIT Technology Review
Source
Generated insight by OnAirToday AI
Accessing proprietary datasets from failed biotech firms offers a shortcut to the high-quality biological data needed to bridge the gap between language models and physical science. This shift signals a transition where AI companies become primary curators and owners of foundational biological research to power the next generation of predictive medicine.
Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.